Oxomemazine
RESPIRATORY SYSTEM
Also known as: doxergan, dysedon, oxomemazin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Oxomemazine is a drug catalogued in DrugCentral.
- ATC code: R06AD08 (Phenothiazine derivatives).
- Molecular formula: C18H22N2O2S; molecular weight 330.45 g/mol.
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R06AD08 | RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Phenothiazine derivatives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Victim of chemical submission | 84.4 |
| Poisoning | 77.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Oxomemazine is on its molecule page.
| Molecular formula | C18H22N2O2S |
|---|---|
| Molecular weight | 330.45 g/mol |
| CAS number | 3689-50-7 |
| InChIKey | QTQPVLDZQVPLGV-UHFFFAOYSA-N |
| PubChem CID | 19396 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is the chemical formula of Oxomemazine?
Oxomemazine has the molecular formula C18H22N2O2S and a molecular weight of 330.45 g/mol.
Browse: all drugs starting with O · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2025 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2104734 — compound record and bioactivity
- PubChem CID 19396 — chemical identifiers
- DrugBank DB13820 — drug record
- FDA UNII 305MB38V1C — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.